Deutivacaftor + Tezacaftor + Vanzacaftor Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 10 mg + 50 mg + 125mg
Reference Brands: Alyftrek (USA)
Category:
Orphan Drugs
Deutivacaftor + Tezacaftor + Vanzacaftor is available in Tablets
and strengths such as 10 mg + 50 mg + 125mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Deutivacaftor + Tezacaftor + Vanzacaftor is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Deutivacaftor + Tezacaftor + Vanzacaftor can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alyftrek is a fixed-dose combination oral medication containing vanzacaftor, tezacaftor, and deutivacaftor, developed for the treatment of cystic fibrosis (CF). The drug is specifically indicated for patients aged six years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vanzacaftor, formulated as vanzacaftor calcium dihydrate, and tezacaftor help improve the processing and trafficking of the defective CFTR protein to the cell surface, while deutivacaftor enhances its function by increasing channel opening probability.
By acting on the underlying genetic defect, Alyftrek improves chloride transport across epithelial cell membranes, helping to hydrate mucus in the lungs and digestive tract. This leads to improved lung function, reduced pulmonary exacerbations, and better overall symptom management in eligible patients. Administered orally once daily, the medication offers a convenient and effective treatment option for cystic fibrosis, supporting long-term disease management and enhancing quality of life. Alyftrek represents a next-generation therapy for CF, providing targeted correction of CFTR protein function in patients with responsive mutations.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing